19 results found.

Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adeno Clinical Trial using veliparib; pegylated liposomal doxorubicin hydrochloride; carboplatin; bevacizumab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin, and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer.
veliparib; pegylated liposomal doxorubicin hydrochloride; carboplatin; bevacizumab; laboratory biomarker analysis

Ovarian Carcinosarcoma, Recurrent Ovarian Epithelial Cancer, Recu Clinical Trial using paclitaxel; carboplatin; ifosfamide

Gynecologic Oncology Group - Recruiting 18 years or older.
- A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary.
paclitaxel; carboplatin; ifosfamide

Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian End Clinical Trial using elesclomol sodium; paclitaxel

Gynecologic Oncology Group - Recruiting 18 years or older.
- A PHASE II EVALUATION OF ELESCLOMOL SODIUM AND WEEKLY PACLITAXEL IN THE TREATMENT OF RECURRENT OR PERSISTENT PLATINUM-RESISTANT OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER.
elesclomol sodium; paclitaxel

Biochemical-recurrent Only Epithelial Ovarian Cancer, Primary Per Clinical Trial using INCB024360; tamoxifen

Incyte Corporation - Recruiting 18 years or older.
- A Randomized, Open-Label, Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer Following Complete Remission With First-Line Chemotherapy.
INCB024360; tamoxifen

Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Can Clinical Trial using ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine; sirolimus; laboratory biomarker analysis; sargramostim

Roswell Park Cancer Institute - Recruiting 18 years or older.
- A Phase I Clinical Trial of mTOR Inhibition With Sirolimus for Enhancing ALVAC(2)-NY-ESO-1(M)/TRICOM Vaccine Induced Anti-Tumor Immunity in Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.
ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine; sirolimus; laboratory biomarker analysis; sargramostim

Ovarian Cancer Clinical Trial using pertuzumab; placebo; chemotherapy

Hoffmann-La Roche - Recruiting 18 years or older.
- A TWO-PART, RANDOMIZED PHASE III, DOUBLE-BLIND, MULTICENTER TRIAL ASSESSING THE EFFICACY AND SAFETY OF PERTUZUMAB IN COMBINATION WITH STANDARD CHEMOTHERAPY VS. PLACEBO PLUS STANDARD CHEMOTHERAPY IN WOMEN WITH RECURRENT PLATINUM-RESISTANT EPITHELIAL OVARIAN CANCER AND LOW HER3 mRNA EXPRESSION.
pertuzumab; placebo; chemotherapy

Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peri Clinical Trial using pegylated liposomal doxorubicin (PLD); VTX-2337; Placebo

VentiRx Pharmaceuticals Inc. - Recruiting 18 years or older.
- A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
pegylated liposomal doxorubicin (PLD); VTX-2337; Placebo

Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Can Clinical Trial using Tivozanib

Northwestern University - Recruiting 18 years or older.
- The Efficacy and Safety of Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Tivozanib

Brenner Tumor, Fallopian Tube Cancer, Ovarian Clear Cell Cystaden Clinical Trial using paclitaxel; docetaxel; carboplatin; bevacizumab; gemcitabine hydrochloride; laboratory biomarker analysis; quality-of-life assessment

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865, IND #113912) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865, IND #113912).
paclitaxel; docetaxel; carboplatin; bevacizumab; gemcitabine hydrochloride; laboratory biomarker analysis; quality-of-life assessment

Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Clinical Trial using veliparib; topotecan hydrochloride; pharmacogenomic studies; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I/II Trial of ABT-888, an Inhibitor of Poly (ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients With Solid Tumors (Phase I) and Relapsed or Refractory Ovarian Cancer or Primary Peritoneal Cancer (Phase II) After Prior Platinum Containing First-Line Chemotherapy.
veliparib; topotecan hydrochloride; pharmacogenomic studies; pharmacological study; laboratory biomarker analysis

Male Breast Cancer, Recurrent Melanoma, Stage IV Breast Cancer, S Clinical Trial using propranolol hydrochloride; Correlative Studies

Ohio State University Comprehensive Cancer Center - Recruiting 18 years or older.
- A Pilot Study of Beta-Blockers in Patients With Advanced Cancer.
propranolol hydrochloride; Correlative Studies

Male Breast Cancer, Recurrent Breast Cancer, Recurrent Fallopian Clinical Trial using mifepristone; carboplatin; gemcitabine hydrochloride; laboratory biomarker analysis; pharmacological study

University of Chicago - Recruiting 18 years or older.
- Carboplatin, Gemcitabine, and Mifepristone for Advanced Breast Cancer and Recurrent or Persistent Epithelial Ovarian Cancer.
mifepristone; carboplatin; gemcitabine hydrochloride; laboratory biomarker analysis; pharmacological study

Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Can Clinical Trial using cabozantinib-s-malate; paclitaxel; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A RANDOMIZED PHASE II STUDY OF NCI SUPPLIED CABOZANTINIB (NSC #761968 IND #116059) VERSUS WEEKLY PACLITAXEL (NSC #673089) IN THE TREATMENT OF PERSISTENT OR RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER.
cabozantinib-s-malate; paclitaxel; laboratory biomarker analysis

Epithelial Ovarian Cancer Clinical Trial using CAELYX; Topotecan HCl

Xian-Janssen Pharmaceutical Ltd. - Recruiting 18 years or older.
- A Phase 3, Randomized, Open-Label, Comparative Bridging Study of CAELYXr Versus Topotecan HCl in Subjects With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy.
CAELYX; Topotecan HCl

Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Can Clinical Trial using wild-type reovirus; paclitaxel

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A RANDOMIZED PHASE II EVALUATION OF WEEKLY PACLITAXEL (NSC# 673089) VERSUS WEEKLY PACLITAXEL WITH ONCOLYTIC REOVIRUS (REOLYSIN NSC # 729968, BB-IND #13370) IN THE TREATMENT OF RECURRENT OR PERSISTENT OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER.
wild-type reovirus; paclitaxel

Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian End Clinical Trial using bortezomib; carboplatin; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A PHASE I PHARMACOKINETIC STUDY OF INTRAPERITONEAL CTEP-SUPPLIED AGENT BORTEZOMIB (PS-341, NSC 681239, IND# 58443) AND CARBOPLATIN (NSC# 241240) IN PATIENTS WITH PERSISTENT OR RECURRENT OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER.
bortezomib; carboplatin; pharmacological study

Fallopian Tube Cancer, Ovarian Cancer, or Primary Peritoneal Cavi Clinical Trial using EGEN-001; pegylated liposomal doxorubicin hydrochloride; RNA analysis; laboratory biomarker analysis

Gynecologic Oncology Group - Recruiting 18 years or older.
- A Phase I Study of Intraperitoneal EGEN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) (IND #12,484) Administered in Combination With Pegylated Liposomal Doxorubicin (PLD, Doxil (NSC #712227 or Lipodox) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
EGEN-001; pegylated liposomal doxorubicin hydrochloride; RNA analysis; laboratory biomarker analysis

Fallopian Tube Cancer, Ovarian Cancer, or Primary Peritoneal Cavi Clinical Trial using carboplatin; ifosfamide; hyperthermia treatment

National Cancer Institute (NCI) - Recruiting 18 years to 65 years.
- A Randomized Phase II/III Trial Comparing Carboplatin-Ifosfamide (IC)-Chemotherapy Vs. IC-Chemotherapy Combined With Extreme Whole Body Hyperthermia In Patients With Recurrence Of Epithelial Ovarian Carcinoma: DOLPHIN-1-STUDY.
carboplatin; ifosfamide; hyperthermia treatment

Epithelial Ovarian Cancer, Which is Platinum Resistant or Refract Clinical Trial using Pazopanib and Cyclophosphamid

University Hospital Heidelberg - Recruiting 18 years or older.
- A Phase I/II Study of Pazopanib (GW786034) and Cyclophosphamide in Patients With Platinum-resistant Recurrent, Pre-treated Ovarian Cancer.
Pazopanib and Cyclophosphamid